Therapeutic supramolecular tubustecan hydrogel combined with checkpoint inhibitor elicits immunity to combat cancer

The clinical benefit of PD-1/PD-L1 blockade immunotherapy is substantially restricted by insufficient infiltration of T lymphocytes into tumors and compromised therapeutic effects due to immune-related adverse events following systemic administration. Some chemotherapeutic agents have been reported...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Biomaterials 2021-12, Vol.279, p.121182-121182, Article 121182
Hauptverfasser:	Wang, Feihu, Su, Hao, Xu, Dongqing, Monroe, Maya K., Anderson, Caleb F., Zhang, Weijie, Oh, Richard, Wang, Zongyuan, Sun, Xuanrong, Wang, Han, Wan, Fengyi, Cui, Honggang
Format:	Artikel
Sprache:	eng
Schlagworte:	Cell Line, Tumor Chemoimmunotherapy Humans Hydrogels Immune checkpoint blockade Immunotherapy Neoplasms - drug therapy Self-supporting hydrogel Supramolecular polymer Sustained release T-Lymphocytes Tumor Microenvironment
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!